白消安联合环磷酰胺作为多发性骨髓瘤患者自体造血干细胞移植预处理方案的初步研究  

Busulfan Combined with Cyclophosphamide as the Conditioning Regimen in Patients with Multiple Myeloma Treated by Autologous Hematopoietic Stem Cell Transplantation

作　　者：金松[1] 徐云[1] 王攀峰[1] 周进[1] 顾斌[1] 李渭阳[1] 周惠芬[1] 傅琤琤[1] 

机构地区：[1]苏州大学附属第一医院血液内科江苏省血液研究所,江苏苏州215000

出　　处：《中国实验血液学杂志》2015年第6期1618-1622,共5页Journal of Experimental Hematology

摘　　要：目的:回顾性分析白消安(BU)联合环磷酰胺(CY)作为多发性骨髓瘤(MM)患者自体造血干细胞移植(Auto-HSCT)预处理方案的安全性及疗效。方法:通过观察20例MM患者经BUCY方案预处理后行Auto-HSCT的不良反应发生情况、造血重建情况、疗效评估及生存情况,分析该预处理方案的安全性及疗效。结果:20例患者,中位年龄52.5(38-66)岁,经Auto-HSCT后中性粒细胞造血重建的中位时间为10(8-17)d,血小板造血重建的中位时间为10(8-18)d,移植100天内无治疗相关死亡(TRM)发生,移植前疗效评估达部分缓解(PR)的患者均获得更为良好的治疗反应,PR率由31.58%下降至0(P<0.05),中位随访8(3-18)个月,仅1例患者疾病进展、并失去最佳治疗反应,而所有患者均存活。结论:BUCY方案作为MM患者Auto-HSCT的预处理方案安全性理想,治疗反应理想,长期疗效尚需观察。Objective:To retrospectively analyze the safety and efficacy of busulfan(BU) combined with cyclophosphamide(CY) as the conditioning regimen of autologous hematopoietic stem cell transplantation(auto-HSCT)in patients with multiple myeloma(MM).Methods:The safety and efficacy of the BUCY regimen were evaluated through observing the adverse reactions,recovery of hematopoietic reconstitution,response and survival in 20 patients after auto-HSCT.Results:In 20 MM patients with median age 52.5(38-66),the neutrophil and platelet counts recovered at 10(8-18) d and 10(8-17) d after auto-HSCT respectively,the treatment related mortality during 100 days after auto-HSCT was 0,the partial remission(PR) rate decreased from 31.58%to 0(P <0.05) after auto-HSCT,only 1 patient was in progression of disease,all patients were alived.Conclusion:For patients with MM treated with Auto-HSCT,the BUCY regimen is ideal in safety and response,but the long-term effect still should be observed.

关 键 词：多发性骨髓瘤 造血干细胞移植 白消安 环磷酰胺 

分 类 号：R733.3[医药卫生—肿瘤]